0
Madrigal Pharmaceuticals, Inc. Banner Image

Madrigal Pharmaceuticals, Inc. has reached its limit for free report views

Work for Madrigal Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

Madrigal Pharmaceuticals, Inc.

  • Ticker MDGL
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Madrigal Pharmaceuticals, Inc. Logo Image
  • 11-50 Employees
  • Based in Conshohocken, Pennsylvania
Madrigal Pharmaceuticals, Inc. (Nasdaq Global Select: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a first-inMore- class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-β selective agonist that is in currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits across a broad spectrum of NASH (non-alcoholic steatohepatitis) and NAFLD (non-alcoholic fatty liver disease) patients.
Madrigal Pharmaceuticals, Inc.

Most Recent Annual Report

Madrigal Pharmaceuticals, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Madrigal Pharmaceuticals, Inc. has reached its limit for free report views.

Older/Archived Annual Reports